Where AI Agents Fit in Healthcare Operations Groundbreaking Study Establishes Non-surgical Treatment Modality for Bowel Function in Individuals Living With Spinal Cord Injury
SpineX’s Proprietary SCONE™ Device Offers New Hope to Individuals Living with Spinal Cord Injury SCONE device…
Invitation to LIDDS Capital Markets Day and presentation of new strategy and vision
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company will host a Capital…
IBEX Announces Results of Annual Meeting
MONTREAL, Feb. 17, 2022 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX…
23andMe to Present at Citi’s 2022 Virtual Healthcare Conference
SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a…
Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022
NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Clearmind Medicine to Host a “Psychedelics for Alcoholism” Event for Investors on February 23
Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for…
Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”),…
Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine…
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company…
POINT Biopharma to Participate in Upcoming Virtual Investor Conferences
INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company”…
Entera Bio to Present at Aegis Virtual Conference on February 23rd
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX),…
AREV Life Sciences Advances Developments, New Appointments and Relationships
VANCOUVER, British Columbia , Feb. 17, 2022 (GLOBE NEWSWIRE) — via InvestorWire – AREV Life…
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community CORAL…
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an…
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference
HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical…
Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update
Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time ATLANTA, Feb….
Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a…
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
Pharmazz Inc. Announces Completion of Enrollment of Phase III Clinical Trial Evaluating Sovateltide as a Treatment for Acute Cerebral Ischemic Stroke
Sovateltide is an endothelin B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects…
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome
Neopharm Gains Exclusive Rights to Commercialize QRX003 in Israel Sixth Distribution Partnership Established Since Quoin’s…